Aortic Aneurysm Market Size, Trends

Aortic Aneurysm Market Overview

Global Aortic Aneurysm Market size is estimated at USD 2665.25 million in 2024 and is expected to reach USD 4064.44 million by 2033 at a 4.8% CAGR.

The global aortic aneurysm market is defined by the increasing prevalence of aneurysmal conditions, with over 200,000 new aortic aneurysm cases diagnosed annually worldwide. Aortic aneurysms, which are abnormal bulges in the wall of the aorta, present a serious risk, with rupture rates as high as 50% if left untreated. Abdominal aortic aneurysms (AAA) account for approximately 75% of all aortic aneurysms, while thoracic aortic aneurysms (TAA) make up the remaining 25%.

Minimally invasive endovascular aneurysm repair (EVAR) procedures now account for more than 60% of AAA treatments due to lower surgical risks and quicker recovery. Increasing usage of imaging technologies, including ultrasound and CT angiography, has led to a rise in early diagnosis, with over 70% of aneurysms being identified at the asymptomatic stage in developed countries. The average patient age at diagnosis is 70 years, and over 80% of patients are male.

With more than 5 million imaging screenings conducted annually across high-risk populations, the demand for accurate, non-invasive diagnostic solutions is rising. Simultaneously, the need for durable and biocompatible stent grafts has spurred innovation in graft materials and delivery systems across manufacturers globally.

Key Findings

Top Driver Reason: Increasing prevalence of abdominal aortic aneurysms among aging male populations.

Top Country/Region: North America dominates due to high screening rates and advanced surgical infrastructure.

Top Segment: Endovascular surgery dominates due to minimally invasive procedures accounting for 60% of all treatments.

Aortic Aneurysm Market Trends

Aortic aneurysm management has evolved with the rapid adoption of endovascular techniques, now representing 60–65% of procedures globally. In the U.S., more than 45,000 EVAR procedures are performed annually. Hospitals increasingly favor EVAR over open repair due to 40% lower hospitalization time and 35% fewer complications.

Advanced diagnostic imaging is a notable trend, with CT and MRI scans contributing to the early detection of over 65% of thoracic and abdominal aneurysms. In Germany alone, annual imaging screenings for aneurysms exceed 400,000. Simultaneously, mobile ultrasound technology adoption has improved screening penetration in rural Asia-Pacific regions, leading to a 20% rise in early diagnosis rates in select provinces of China.

Biocompatible graft materials with enhanced tensile strength and reduced thrombogenicity are gaining traction. Companies are focusing on polymer-based endografts that offer flexibility and durability, with new prototypes showing a 50% reduction in endoleak rates. Furthermore, 3D printing is being increasingly used to personalize grafts, with hospitals in Japan and Italy conducting clinical trials involving patient-specific stent grafts for complex anatomies.

Another rising trend includes robotic-assisted surgery, currently adopted in over 100 high-volume centers globally, reducing procedural times by 15% and improving stent placement precision.

Additionally, telemedicine has entered the aortic aneurysm market, with more than 25% of follow-up consultations now done virtually, especially in North America and parts of Europe. This trend is enabling more efficient patient monitoring and reducing post-surgery readmissions by up to 18%.

Aortic Aneurysm Market Dynamics

DRIVER

Rising demand for minimally invasive aortic aneurysm repair.

Increased patient preference for less invasive options has made endovascular procedures the standard for aortic aneurysm treatment. Over 60% of all abdominal aneurysms are now managed via EVAR procedures. This shift is driven by 40% lower post-operative recovery time, reduced hospital stays (average 2–3 days vs. 7–10 days for open repair), and significantly improved survival rates post-intervention. An aging global population, with more than 650 million people aged 65 and above, amplifies the demand for minimally invasive and low-risk treatment alternatives.

RESTRAINT

Limited access to surgical infrastructure in low-income regions.

Despite high mortality risks, aortic aneurysm procedures are often delayed or unavailable in developing countries due to the lack of advanced surgical and diagnostic infrastructure. In Sub-Saharan Africa, less than 10% of aneurysm patients receive timely intervention. Lack of awareness, trained vascular surgeons, and low penetration of high-quality imaging systems hinders early detection and treatment, contributing to mortality rates of up to 80% in untreated cases. This infrastructural gap remains a significant restraint.

OPPORTUNITY

Technological innovation in personalized grafts and robotic surgery.

Emerging technologies such as AI-guided imaging diagnostics and robotic-assisted stent placements are revolutionizing the market. Personalized endografts, based on patient-specific aortic measurements using 3D printing, are being trialed in more than 50 global institutions. Early results show a 35% improvement in surgical precision and a 20% decrease in endoleak complications. Additionally, real-time navigation systems integrated with robotic tools are cutting down procedure times and optimizing surgical outcomes, particularly in complex thoracic cases.

CHALLENGE

Rising costs and healthcare expenditures.

Aortic aneurysm treatment, especially via EVAR, involves high costs for stent grafts, imaging, and hospitalization. In the U.S., average EVAR procedure costs exceed $30,000. These rising costs strain both public and private healthcare systems, limiting affordability in middle-income populations. Reimbursement challenges and pricing pressures on medical device manufacturers further complicate market expansion. As a result, balancing innovation and affordability remains a key challenge.

Aortic Aneurysm Market Segmentation

The aortic aneurysm market is segmented by type and application. By type, the market includes medicine-based management, surgical repair, and others. By application, the focus is on hospitals, clinics, and specialty care centers. Hospitals account for over 70% of all aortic aneurysm surgeries due to access to vascular units and surgical equipment. Clinics and outpatient centers are increasingly managing follow-ups and diagnostics, with over 30% of follow-up appointments in urban centers conducted outside hospitals.

By Type

Medicine: Medical management, including antihypertensives and statins, is employed in early-stage aneurysms under 5 cm in diameter. Nearly 30% of patients globally fall into this category, particularly those deemed high-risk for surgery. Beta-blockers and ACE inhibitors are prescribed in 60% of such cases to manage blood pressure and prevent aneurysm expansion.
Surgery: Surgical repair—either open or endovascular—is the definitive treatment for aneurysms exceeding 5.5 cm. Open surgery accounts for approximately 35% of global procedures, primarily in regions with limited access to endovascular tools. EVAR, representing 65% of interventions, is preferred in North America, Europe, and parts of Asia due to reduced hospital stays and fewer complications.
Other: Other modalities include surveillance programs, with more than 500,000 patients under active monitoring globally. Additionally, investigational therapies such as gene expression blockers and anti-inflammatory biologics are in early trial phases.

By Application

Hospital: Hospitals dominate with more than 70% of surgical interventions and all high-risk emergency care. In the U.S., over 90% of thoracic aneurysm cases are treated in tertiary hospitals with cardiothoracic units. Hospitals also manage perioperative diagnostics and intensive post-operative care.
Clinic: Clinics primarily handle routine screenings, risk assessments, and medical management. In Europe, over 40% of AAA cases under 5 cm are monitored through clinic-based programs, with follow-up every 6–12 months using ultrasound imaging.
Other: Home healthcare and telemedicine are becoming relevant, with nearly 20% of follow-up patients in North America using wearable blood pressure monitors linked to healthcare networks for remote management.

Aortic Aneurysm Market Regional Outlook

The aortic aneurysm market shows strong regional variation based on access to healthcare, screening policies, and surgical expertise.

North America

The U.S. leads globally, with more than 70,000 aortic aneurysm procedures performed annually. EVAR adoption exceeds 80% for AAA repairs. Over 90% of men aged 65+ undergo one-time screening as recommended by healthcare guidelines. High reimbursement rates and the presence of major companies contribute to market dominance.

Europe

Europe accounts for over 30% of global aneurysm procedures, with Germany, the UK, and France leading in EVAR adoption. Over 250,000 individuals are screened annually in Germany. Public health initiatives and the availability of advanced imaging drive early diagnosis, with detection rates above 60%.

Asia-Pacific

Asia-Pacific is emerging rapidly, with Japan and China accounting for over 100,000 diagnosed cases combined. Japan has high screening penetration (above 65% in men over 65). In contrast, rural India and Southeast Asia lag due to limited access. However, investment in mobile diagnostics and rising vascular surgeon numbers in China support growth.

Middle East & Africa

This region faces infrastructural challenges. Fewer than 10% of patients in Sub-Saharan Africa receive timely surgery. In the Middle East, particularly in the UAE and Saudi Arabia, investment in tertiary care hospitals and screening programs is improving outcomes, with AAA detection rates reaching 40% in urban populations.

List of Top Aortic Aneurysm Market Companies

Medtronic
Endologix
Gore Medical
MicroPort Scientific
Cook Medical
Terumo Medical
MAQUET Holding
Lombard Medical
JOTEC
Cardinal Health

Top Two Companies with Highest Share

Medtronic: Performs over 20,000 EVAR procedures annually using its Endurant systems; leads with over 30% procedural use in developed markets.

Gore Medical: With its Excluder line, it holds over 20% of EVAR market share globally, especially dominant in Europe.

Investment Analysis and Opportunities

Investments in the aortic aneurysm market are largely directed toward advanced diagnostics, surgical innovation, and emerging markets infrastructure. With over 700,000 people globally at risk of aneurysm rupture annually, there is an urgent demand for proactive diagnostics and intervention systems. Venture capital and private equity funds have shown increasing interest in startups focusing on AI-based aneurysm risk prediction platforms and image-guided surgical tools. In the past three years alone, over $500 million has been invested in AI-powered vascular imaging systems, with companies developing algorithms capable of identifying high-risk aneurysms based on shape, wall tension, and hemodynamic parameters.

Device manufacturers are investing heavily in the development of polymer-based and hybrid grafts, with R&D budgets increasing by nearly 15% annually in the top five multinational firms. These investments are directed toward addressing endoleak complications, which affect over 10% of EVAR patients post-surgery. Furthermore, hospitals are also allocating funds toward robotic systems, which reduce complications by up to 20% and improve surgeon ergonomics.

In developing regions, multilateral health organizations are funding screening and training programs to expand diagnosis and treatment availability. In India, $80 million was allocated in 2023 for regional vascular training centers, aimed at improving aneurysm intervention capabilities in tier-2 and tier-3 cities.

Japan and South Korea are investing in patient-specific graft technology, with at least 10 clinical trials running across leading vascular institutions. These trials represent a potential opportunity for manufacturers of customized stents and delivery systems. The growing demand for home-based monitoring devices and wearable biosensors—used by over 150,000 patients globally post-surgery—also opens investment pathways for med-tech companies.

New Product Development

Innovation in the aortic aneurysm market is centered around three key pillars: stent graft evolution, imaging accuracy, and patient-specific treatment solutions. Over the past two years, more than 30 new product trials have been launched focusing on next-generation endografts that address challenges like endoleaks and migration.

Medtronic recently launched a modular stent graft platform capable of adapting to complex aortic anatomies. This system allows for in-situ customization and has been trialed in over 500 patients globally, showing a 25% improvement in deployment accuracy. Gore Medical has developed a low-profile delivery system, reducing femoral access complications in patients with small vessel diameters—a problem affecting 15–20% of elderly aneurysm patients.

Advancements in graft coatings have led to the development of bioactive surfaces that reduce thrombosis. A new coating trialed by a leading U.S. company showed a 30% reduction in post-implant clotting over 12 months. Additionally, flexible polymer-based stents are gaining ground, allowing for higher conformability and deployment precision. These materials can endure up to 10 million pulsatile cycles, demonstrating enhanced durability.

3D printing is also revolutionizing custom graft production. Hospitals in Japan and Italy have performed over 100 patient-specific implantations using 3D-printed templates, achieving near-zero deployment mismatches. In parallel, robotic-assisted EVAR systems are being developed, capable of automated wire navigation and graft positioning. Early pilot programs in Germany and the U.S. show a 15% reduction in total surgical time and higher placement precision.

Five Recent Developments

Medtronic: Launched the Endurant™ II system with enhanced deployment tracking, now used in 30+ countries with 10,000 implants recorded in 12 months.
Gore Medical: Introduced a new Excluder® LP system with ultra-low profile and improved radial force, reducing procedural time by 18% in clinical trials.
Cook Medical: Initiated a trial for a next-generation thoracic stent graft system with 3-zone sealing, aiming to reduce endoleaks in high-risk cases.
MicroPort Scientific: Expanded manufacturing in Asia-Pacific with a facility in Suzhou capable of producing 15,000 units annually to meet growing regional demand.
Terumo Medical: Unveiled its AI-enabled vascular imaging platform, which is now deployed in 50 hospitals in Japan, showing 20% faster diagnosis times.

Report Coverage of Aortic Aneurysm Market

This report provides a comprehensive and structured analysis of the aortic aneurysm market across critical dimensions such as product type, clinical applications, regional dynamics, top players, and technological innovations. Covering over 30 data-driven sections, the report quantifies the market by procedure volume, device penetration, diagnostic usage, and regional case distribution.

Detailed segmentation includes surgical types—open repair versus endovascular—and medical management across geographies and risk profiles. Applications across hospitals, clinics, and alternative care facilities are examined with performance metrics such as intervention rate, post-operative recovery duration, and imaging frequency per capita.

By type, the report includes data on over 500,000 annual surgical interventions, of which EVAR accounts for approximately 60–65%, while open repair covers the remaining 35–40%. By region, the report highlights performance metrics such as screening rates (above 85% in North America), stent graft adoption (over 70% in developed markets), and mortality reduction post-intervention (over 40%).

The competitive landscape is evaluated with benchmarks on product portfolios, procedure volumes, and innovation pipelines for top players. Medtronic and Gore Medical are analyzed in-depth based on deployment scale, technology evolution, and clinical outcomes.